Ofloxacin

General Toxicity Notes
Most agents in this group are malabsorbed in the presence of compounds that contain metals such as magnesium, calcium, aluminum, and iron. Poorly absorbed with antacids, sucralfate, and phosphate binders.
Excreted Unchanged %
68-80
Half-Life (Normalesrd) Hours
5-8/28-37
Plasma Protein Binding %
25
Volume Of Distribution L/Kg
1.5-2.5
Dose For Normal Renal Function
200-400 mg q12h
Adjustment For Renal Failure Method
D
Adjustment For Renal Failure Gfr, Ml/Min >50 [Recommended Level]
100% [A]
Adjustment For Renal Failure Gfr, Ml/Min 10-50 [Recommended Level]
200-400 mg q24h [A]
Adjustment For Renal Failure Gfr, Ml/Min <10 [Recommended Level]
200 mg q24h [A]
Supplement For Dialysis [Recommendation Level]: Ihd
IHD: 100-200 mg after dialysis
Supplement For Dialysis [Recommendation Level]: Pd
PD: Dose for GFR <10
Supplement For Dialysis [Recommendation Level]: Crrt
CRRT: 300 mg q24h (recommendation differs from referenced publication; use own judgment), [B]
References
Eliopoulos GM. New quinolones: pharmacology, pharmacokinetics, and dosing in patients with renal insufficiency. Rev Infect Dis. 1988; 10 Suppl 1: S102-5. [PMID: 3279486] / Fillastre JP, Leroy A, Humbert G. Ofloxacin pharmacokinetics in renal failure. Antimicrob Agents Chemother. 1987; 31: 156-60. [PMID: 3471179] / Fillastre JP, Leroy A, Moulin B, Dhib M, Borsa-Lebas F, Humbert G. Pharmaco-kinetics of quinolones in renal insufficiency. J Antimicrob Chemother. 1990; 26 Suppl B: 51-60. [PMID: 2124213] / Fuhrmann V, Schenk P, Mittermayer C, El Menyawi I, Ratheiser K, Thalhammer F. Single-dose pharmacokinetics of ofloxacin during continuous venovenous hemofiltration in critical care patients. Am J Kidney Dis. 2003; 42: 310-4. [PMID: 12900813] / Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S. Ofloxacin pharmacokinetics in chronic renal failure and dialysis. Clin Pharmacokinet. 1991; 21: 357-71. [PMID: 1773550] / Lode H, H&#246; ffken G, Prinzing C, Glatzel P, Wiley R, Olschewski P, et al. Comparative pharmacokinetics of new quinolones. Drugs. 1987; 34 Suppl 1: 21-5. [PMID: 3481323] / Mueller BA, Pasko DA, Sowinski KM. Ofloxacin clearance during continuous hemofiltration [Letter]. Am J Kidney Dis. 2003; 42: 1326-7; author reply 1327-8. [PMID: 14655211] / White LO, MacGowan AP, Mackay IG, Reeves DS. The pharmacokinetics of ofloxacin, desmethyl ofloxacin and ofloxacin N-oxide in haemodialysis patients with end-stage renal failure. J Antimicrob Chemother. 1988; 22 Suppl C: 65-72. [PMID: 3182464] / Wolfson JS, Hooper DC. Pharmacokinetics of quinolones: newer aspects. Eur J Clin Microbiol Infect Dis. 1991; 10: 267-74. [PMID: 1864287]